Five Prime Therapeutics announces expansion of license agreement with GSK
Five Prime Therapeutics announced an expansion of its respiratory disease research collaboration with GSK that was established in 2012 to identify first-in-class agents and new mechanisms for the treatment of refractory asthma and chronic obstructive pulmonary disease. October 23, 2014